You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Article metrics

Article menu

Download PDFPDF

XML
Interstitial lung disease
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

 

Online download statistics by month:

Online download statistics by month: September 2017 to September 2024

AbstractFullPdf
Sep 2017221221117
Oct 2017209209137
Nov 201713713678
Dec 201710510541
Jan 2018989935
Feb 201811811749
Mar 201817417446
Apr 201815115162
May 201815615757
Jun 201819219354
Jul 201823023047
Aug 201823623554
Sep 201817717748
Oct 201828928847
Nov 201827126958
Dec 201834934976
Jan 201932131962
Feb 201931131265
Mar 201928028077
Apr 201918218167
May 201921221070
Jun 201922422368
Jul 201917217279
Aug 201919219248
Sep 201919519579
Oct 2019277277114
Nov 201915715653
Dec 201918518595
Jan 202016616652
Feb 202022122059
Mar 202070970963
Apr 202010210131
May 202011011072
Jun 202010710656
Jul 202013813752
Aug 2020908946
Sep 202013913452
Oct 202015114676
Nov 20201029763
Dec 2020888741
Jan 2021989557
Feb 2021989838
Mar 202115815991
Apr 202111810460
May 2021969570
Jun 2021949360
Jul 202111711752
Aug 2021878645
Sep 2021747250
Oct 2021969763
Nov 20217878100
Dec 2021838334
Jan 2022656829
Feb 2022947345
Mar 2022796749
Apr 2022948741
May 2022858849
Jun 2022666228
Jul 2022675821
Aug 2022858437
Sep 2022716636
Oct 20221098747
Nov 2022977449
Dec 2022595417
Jan 2023857526
Feb 20231029645
Mar 20231039436
Apr 2023686022
May 2023735834
Jun 2023565027
Jul 2023666233
Aug 2023443419
Sep 2023807128
Oct 20231109421
Nov 202316915421
Dec 202320319228
Jan 2024121121144
Feb 202413412718
Mar 202410895129
Apr 202413312139
May 202417916936
Jun 2024958534
Jul 20241099843
Aug 2024928221
Sep 202411310225
Total12355119994543